To investigate the potential beneficial effect of fecal microbiota transplantation (FMT) on gastrointestinal symptoms, gut dysbiosis and immune status in discharged COVID-19 patients.
Case presentation
A total of 11 COVID-19 patients were recruited in April, 2020, about one month on average after they were discharged from the hospital. All subjects received FMT for 4 consecutive days by oral capsule administrations with 10 capsules for each day. In total, 5 out of 11 patients reported to be suffered from gastrointestinal symptoms, which were improved after FMT. After FMT, alterations of B cells were observed, which was characterized as decreased naive B cell (P = 0.012) and increased memory B cells (P = 0.001) and non-switched B cells (P = 0.012).The microbial community richness indicated by operational taxonomic units number, observed species and Chao1 estimator was marginally increased after FMT. Gut microbiome composition of discharged COVID-19 patients differed from that of the general population at both phylum and genera level, which was characterized with a lower proportion of Firmicutes (41.0%) and Actinobacteria (4.0%), higher proportion of Bacteroidetes (42.9%) and Proteobacteria (9.2%). FMT can partially restore the gut dysbiosis by increasing the relative abundance of Actinobacteria (15.0%) and reducing Proteobacteria (2.8%) at the phylum level. At the genera level, Bifidobacterium and Faecalibacterium had significantly increased after FMT.
Conclusions
After FMT, altered peripheral lymphocyte subset, restored gut microbiota and alleviated gastrointestinal disorders were observe, suggesting that FMT may serve as a potential therapeutic and rehabilitative intervention for the COVID-19.
Hinweise
Fengqiong Liu, Shanliang Ye and Xin Zhu contributed equally to this work
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Introduction
Fever and cough are the most common clinical manifestations of COVID-19 infection. In addition, the disease can also cause digestive symptoms such as nausea and diarrhea [1, 2], which may be largely underestimated [3]. Apart from these, lymphopenia and hypercytokinemia were also common in COVID-19 patients which suggest that COVID-19 could compromise the immune system [4, 5]. The presence of both lymphopenia and hyper-cytokinemia in COVID-19 patients might indicate the severity of pathogen infection, as previously reported in severe influenza patients during the pandemic of coronavirus (SARS-CoV) in 2003 [6, 7].
Tens of trillions of microbiota are colonized on the mucosal surfaces of the human body such as intestine and respiratory tract. In the past decades, large amount of evidence emerged to support the beneficial effects of commensal bacteria, especially probiotics. In addition to their crucial role in maintaining immune homeostasis of the intestine, studies also reported that commensal bacteria exerts a marked influence on the immune responses at other mucosal surfaces such as the respiratory tract to protect against respiratory influenza virus [8]. Siew C et al. observed persistent alterations in the fecal microbiome of SARS-CoV-2 infected patients during the time of hospitalization, which may suggest that targeting gut microbiota is a new therapeutic option or at least is a choice of adjuvant therapy for COVID-19 [9].
Anzeige
Fecal microbiota transplantation (FMT), an effective way to restore gut microbiota [10], was reported to enhance immunity and would be a potential therapy for individuals with pathogen infection [11‐14]. Bradley et al. reported that antibiotic treatment can reduce intestinal microbiota, thus change the interferon signature driven by commensal in lung epithelia and promote early influenza virus replication in the respiratory tract. The effects can be reversed by FMT [15]. Therefore, it is very likely that FMT can enhance immunity and would be a potential therapy for individuals with virus infection. Given the fact that gastrointestinal symptoms and immunity dysfunction is prevalent in COVID-19 patients, we speculate that FMT can bring beneficial effect on the gut microbiota, gastrointestinal disorders and immunity system after SARS-CoV-2 infection. In this pilot study, we recruited 11 discharged COVID-19 patients in March, 2020 in Jiangxi Province and conducted FMT to investigate the potential benefit effect of FMT on the gut dysbiosis and immune system.
Methods
Study participants
This was a prospective, interventional, single-centered pilot study of FMT performed in the Ganzhou city in Jiangxi province of China. The local ethics committee approved the study (Approval number: 2020001) and patients provided written informed consent. In total, 76 COVID-19 cases were confirmed in Ganzhou city since the disease outbreak. In April 2020, we recruited 11 COVID-19 patients who were initially admitted to the Fifth People’s Hospital of Ganzhou City from January 26 to March 4, 2020. The patients were released from hospital from February 13 to March 23, 2020. All the patients were laboratory confirmed positive COVID-19 cases. The timeline of patient diagnosis, discharge and recruitment was summarized (Fig. 1). All the subjects were abstinent from antibiotics or anti-inflammatory drug for two weeks prior to the treatment.
Fig. 1
The timeline of patient diagnosis, discharge and recruitment. In total, 11 COVID-19 patients were diagnosed and admitted to the Hospital from January 26 to March 4, 2020. The patients were discharged from hospital from February 13 to March 23, 2020. The recruitment was initiated in April 3, 2020.
×
Data collection
General information included age, sex, occupation, origin, diagnosis date of COVID-19, severity assessment on admission, and the discharged date, which were collected by face to face interview. Intestinal symptoms including constipation, diarrhea, abdominal pain, gastralgia, acid reflux, gastrectasia, as well as fatigue, depression, anxiety, insomnia were obtained by questionnaire.
Laboratory findings
Laboratory test were evaluated and collected before and after FMT. Laboratory tests included blood routine (leucocytes, neutrophils, lymphocytes, platelets, erythrocyte, haemoglobin), Blood biochemistry (albumin, globulin, A/G, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, serum creatinine).
Anzeige
Lymphocyte subset
Peripheral blood was obtained before and one week after FMT treatment in EDTA tubes for lymphocyte subset detection. All samples were tested within 6 hours after collection. Briefly, 69 indicators were measured by multiple-color flow cytometry with hundreds of human flow monoclonal antibody according to the manufacturer’s instructions. The cells were analyzed on a BDFACS Canto II flow cytometry system (BD Biosciences).The finally lymphocyte subset data was presented as percentage.
FMT treatment
Protocol of donor screening, FMT capsule preparation, treatment regimen was summarized. Oral capsule administrations were performed in a monitored clinical setting. Participants received 10 capsules each day for 4 consecutive days. The oral capsules prepared for each participant were from a single donor to guarantee the procedure is traceable. Potential side effects such as fever, headache and gastrointestinal symptoms such as diarrhea, nausea, vomiting, distention, abdominal pain were monitored during FMT.
Gut Microbiome assessments by 16s sequencing
Fecal samples were collected before and one week after FMT. A detailed description of donor stool sampling, 16s sequencing and data processing were summarized. Briefly, sampling packages were distributed to participants and fecal samples were collected and stored in a sealed container which was transported with frozen gel packs to provide a low temperature environment until delivered to the laboratory. Fecal samples were pre-treated and gut microbiome were characterized by 16S sequencing. Original sequencing analysis was performed using QIIME2 and the Silva database was used for taxonomic assignments.
Statistical analyses
Continuous variable were presented as median and interquartile range. Categorical variable were present as percentage. A paired sample t-test was adopted for comparison of variable between pre- and post-FMT for normally distributed data, while Wilcoxon matched-pairs test were performed for data with skewed distribution. The diversity indices evaluating gut microbial community richness (the Chao1 estimator) and alpha diversity (the Shannon and Simpson estimator) were calculated using Mothur.
Patient and public involvement
Neither patients nor the public were involved in the conception or conduct of the study.
Results
Basic information of the 11 COVID-19 patients treated with oral encapsulated FMT
A total of 11 COVID-19 patients who were cured and discharged from the hospital were recruited in the study (Table 1). The median age was 49 years with an interquartile range of 47–57, and 6 patients (54.5%) were male. As for the degree of disease severity on admission, 10 participants were categorized as non-severe. Non-severe was defined as no radiographic evidence of pneumonia or pneumonia was present along with fever and respiratory tract symptoms, but without obvious oxygen saturation change or respiratory failure requiring mechanical ventilation, shock, or organ failure requiring intensive care. One participant was categorized as severe, who suffered from shock and required intensive care.
Table 1
Basic information of 11 COVID-19 patients
Patient number
Age, years
Sex
Date of diagnosis
Date of discharge
Severity of Covid-19 on admission
1
57
Male
2020/1/28
2020/2/22
Non-severe
2
51
Female
2020/1/28
2020/2/14
Non-severe
3
45
Male
2020/2/7
2020/2/22
Non-severe
4
49
Male
2020/1/26
2020/2/21
Non-severe
5
49
Female
2020/1/26
2020/2/21
Non-severe
6
23
Female
2020/1/28
2020/2/13
Non-severe
7
48
Male
2020/2/2
2020/2/24
Non-severe
8
47
Male
2020/1/30
2020/2/20
Non-severe
9
58
Male
2020/3/4
2020/3/23
Non-severe
10
68
Female
2020/1/29
2020/2/19
Non-severe
11
53
Female
2020/2/28
2020/3/20
Non-severe
Gastrointestinal symptoms and lab results of 11 COVID-19 patients before and after FMT
In total, 5 out of 11 discharged patients presented gastrointestinal symptoms to some extent which included constipation, diarrhea, abdominal pain, gastralgia, acid reflux and gastrectasia (Table 2). GI symptoms were present during the admission and persisted beyond discharge. No patient reported GI symptoms before the disease.
Table 2
Symptoms of 11 COVID-19 patients before and after fecal microbiota transplantation
Symptoms
Pre-FMT n(%)
Symptoms relieved Post-FMT n(%)
Constipation
3 (27.3%)
3 (27.3%)
Diarrhea
1 (9.1%)
1 (9.1%)
Abdominal pain
1 (9.1%)
1 (9.1%)
Gastralgia
1 (9.1%)
1 (9.1%)
Acid reflux
2 (18.2%)
1 (9.1%)
Gastrectasia
1 (9.1%)
1 (9.1%)
GI symptoms (in total)
5 (45.5%)
5 (45.5%)
Fatigue
3 (27.3%)
2 (18.2%)
Depression and anxiety
2 (18.2%)
1 (9.1%)
Insomnia
3 (27.3%)
3 (27.3%)
Psychological symptoms (in total)
5 (45.5%)
4 (36.4%)
Values are expressed in number (percentage)
After FMT, 5 subjects reported alleviation in gastrointestinal symptom.
Anzeige
Most of the lab results including blood routine and blood biochemistry were within the normal range in discharged COVID-19 patients (Table 3). 8 out of 11(72.7%) study subjects had mildly decreased Albumin/Globulin ratio, which showed no obvious improvement after FMT.
Table 3
Lab results of 11 COVID-19 patients pre- and post-fecal microbiota transplantation
Blood routine
Pre-FMT
Post-FMT
Leucocytes (× 109 per L; normal range 3.5–9.5)
5.6 (4.8, 6.5)
5.9 (4.7, 6.8)
Neutrophils (× 109 per L; normal range 1.8–6.3)
3.2 (2.9, 3.6)
3.3 (2.6, 4.1)
Lymphocytes (× 109 per L; normal range 1.1–3.2)
1.7 (1.6, 2.3)
1.8 (1.6, 2.2)
Monocytes (× 109 per L; normal range 0.1–0.8)
0.4 (0.3, 0.4)
0.4(0.3, 0.5)
Erythrocyte (× 1012 per L; normal range 3.5–5.1)
4.8 (4.3, 5.5)
4.8 (4.5, 5.3)
Increased
2 (18.2%)
2 (18.2%)
Haemoglobin (g/L; normal range 120–175)
133 (130, 146)
133 (130, 151)
Increased
1 (9.1%)
1 (9.1%)
Decreased
0 (0.0%)
1 (9.1%)
Platelets (×109 per L; normal range 125–350)
262 (239, 297)
257 (182, 295)
Increased
2 (18.2%)
2 (18.2%)
Blood biochemistry
ALT (U/L; normal range 9.0–50.0)
18.0 (13.0, 23.0)
15.0 (14.8, 22.0)
AST(U/L; normal range 15.0–40.0)
19.6 (18.0, 20.4)
18.0 (17.0, 21.0)
AST/ALT( normal range 0–3)
1.1 (0.9, 1.5)
1.1 (0.9, 1.4)
Albumin ( 34–54 g/L )
43.0 (40.1, 43.2)
43.0 (42.0, 44.0)
Globulin (20–45 g/L)
30.8 (28.1, 32.3)
30.7 (28.8, 32.4)
A/G ( 1.5-2.5)
1.4 (1.3, 1.5)
1.4 (1.3, 1.5)
Decreased
8 (72.7%)
8 (72.7%)
Blood urea nitrogen (mmol/L; normal range 3.6–9.5)
4.9 (4.0, 5.9)
5.0 (4.5, 5.4)
Increased
1 (9.1%)
1 (9.1%)
Serum creatinine (μmol/L; normal range 57.0–111.0)
77.1 (62.9, 83.0)
79.2 (62.4, 84.0)
Values are expressed in number (percentage) and median (interquartile range)
In addition to blood routine test, we analyzed lymphocyte subsets composition by flow cytometry. We obtained detailed expression information of 69 different types of lymphocyte and all the lymphocytes were classified into five major subsets, CD4+ T cells (n = 17), CD8+ T cells (n = 18), γδT cells (n = 12),B cells (n = 12) and NK cells (n = 10). FMT exert significant effect on B lymphocytes which was characterized as decreased naive B cells (P = 0.012), increased memory B cells (P = 0.001 and non-switched B cells (P = 0.012). In addition, the proportion of double positive T cells increased after FMT (P = 0.012). γδT cells also showed marginal difference after FMT (Table 4).
Table 4
Proportion of lymphocyte subset before and after fecal microbiota transplantation
Pre-FMT
Post-FMT
P value
T cells
64.0 (56.2, 70.9)
62.2 (54.5, 71.6)
% of lymphocyte
0.663
Helper T cells
56.4 (53.8, 66.2)
55.0 (52.0, 62.9)
% of T cells
0.333
Killer T cells
27.1 (22.7, 33.8)
28.2 (24.1, 33.4)
% of T cells
0.062
Double positive T cells
0.8 (0.5, 3.5)
1.1 (0.7, 2.9)
% of T cells
0.012
Th to Tc ratio
2.1 (1.6, 2.5)
2.0 (1.7, 2.5)
–
0.673
γδT cells
1.4 (1.0, 5.3)
4.4 (2.0, 7.6)
% of T cells
0.149
NK cells
13.2 (9.5, 18.7)
13.3 (8.9, 18.6)
% of lymphocyte
0.938
Immature NK cells
5.1 (3.8, 8.4)
7.4 (4.8, 8.3)
% of NK cells
0.936
Mature NK cells
93.3 (91.6, 96.2)
91.9 (91.5, 95.3)
% of NK cell
0.966
Immature/mature NK cells
0.05 (0.04, 0.09)
0.08 (0.05, 0.09)
–
0.905
B cells
10.9 (7.6, 14.0)
8.3 (3.7, 11.5)
% of lymphocyte
0.012
Naïve B cells
62.2 (54.3, 69.1)
40.8 (32.8, 65.2)
% of B cells
0.012
Memory B cells
25.3 (20.2, 30.8)
37.4 (26.3, 48.2)
% of B cells
0.001
Non-switched B cells
10.2 (7.8, 15.2)
21.9 (13.7, 26.0)
% of B cells
0.012
Immature regulatory B cells
0.5 (0.3, 0.8)
1.0 (0.2, 3.0)
% of B cells
0.054
Values are expressed in number (percentage) and median (interquartile range)
FMT fecal microbiota transplantation, T cells T lymphocyte, NK cells natural killer cell, B cells B lymphocytes
Alterations of gut microbiota in discharged COVID-19 patients after FMT
In 22 fecal samples, 970,334 sequencing reads were obtained, and an average of 213 OTUs was identified for each sample. The microbial community richness indicated by OTUs number, observed species and Chao1 estimator was marginally increased after FMT, whereas the alpha diversity estimated by the Shannon and Simpson index showed no significant alteration after FMT (Table 5).
Table 5
Community richness and diversity of Gut Microbiota
Pre-FMT
Post-FMT
P value
OTU num
178 (148, 262)
226 (205, 258)
0.101
Observed species
170 (139, 248)
218 (194, 246)
0.100
Chao1 index
225 (182, 305)
293 (257, 327)
0.060
Shannon index
3.78 (3.19, 4.38)
3.41 (3.05, 24.43)
0.800
Simpson index
0.85 (0.80, 0.88)
0.7946 (0.72, 0.89)
0.904
Values are expressed in median (interquartile range)
FMT fecal microbiota transplantation, OTU operational taxonomic unit
At the phylum level, the top 5 phylum at baseline include Firmicutes (41.0%), Bacteroidetes (42.9%), Proteobacteria (9.2%),Actinobacteria(4.0%),
Anzeige
Fusobacteria (2.8%). The top 5 phylum after FMT included Firmicutes (41.5%), Bacteroidetes (39.3%),Actinobacteria(15%), Proteobacteria (2.8%),
Fusobacteria (1.3%). The relative abundance of Proteobacteria decreased, while Actinobacteria increased after intervention (P<0.001) (Fig. 2).For individual patient, patient No. 1, who had moderate constipation but greatly improved after FMT, was characterized with high proportion of Firmicutes(67.8%) and Fusobacteria (22.7%)and absence of Bacteroidetes (3.7%). FMT significantly increased Bacteroidetes (62.6%), decreased Firmicutes (26.0%) and Fusobacteria (9.2%). Patient No. 7 was a severe COVID-19 survivor who suffered from diarrhea. The patient presented a microbiome profile of extremely high Bacteroidetes (84.4%) and low relative abundance of Firmicutes (12.3%). After FMT, the proportion of Bacteroidetes (45.7%) decreased and Firmicutes increased (48.7%). Patient No.11 suffered from severe constipation, gut microbiota profile of whom showed high proportion of Actinobacteria (28.6%) and Proteobacteria (37.2%), whereas low abundance of Bacteroidetes (0.2%). Significant decrease in abundance of Proteobacteria (2.5%) was observed after FMT.
Fig. 2
Alterations of gut microbiota in discharged COVID-19 patients after FMT. Alterations of gut microbiota were presented at the phylum and genera level. a Changes of relative abundance of individual phylum for both individual patients and at average level were presented. b Changes of relative abundance of individual genus for both individual patients and at average level were presented. c Heatmap of changes in relative abundance of the top 15 genera. A# represent pre-FMT, B# represent post-FMT.
×
At the genera level, the top 5 genera before FMT included Bacteroides (28.3%), Prevotella (13.0%), Faecalibacterium (6.5%), Lachnospiraceae (6.2%), Phascolarctobacterium(5.7%) at baseline, while after FMT the top 5 genera include Bacteroides (31.1%),Faecalibacterium(11.7%), Prevotella (6.6%), Bifidobacterium (10.4%), Collinsella (4.5%) (Fig. 2). Bifidobacterium, Faecalibacterium, Collinsella significantly increased after FMT. For individual patient, patient No. 1 was characterized with high proportion of Fusobacterium (22.7%), Lachnospiraceae (16.6%), Blautia (16.1%), ClostridiumXlVa (11.1%). After FMT, Bacteroides (61.9%) increased, whereas proportions of Blautia (0.25%), ClostridiumXlVa (1.0%), Lachnospiraceae (1.6%), Fusobacterium (9.2%) were decreased. Patient No.7 with severe COVID-19 presented high proportion of Prevotella (82.5%) which was decreased (0.01%), while Bacteroides (44.4%) and Phascolarctobacterium (27.8%) increased after FMT. Patient No.11 had high proportion of Enterobacteriaceae (30.7%) and Collinsella (20.9 %). After FMT, relative abundance of Enterobacteriaceae decreased (1.2%), while Bifidobacterium significantly increased (36.7%).
Side effects of FMT
Potential side effects included gastrointestinal symptoms such as diarrhea, abdominal pain were monitored during FMT.
Anzeige
Informed consent
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Discussion
We are for the first time followed up COVID-19 patients after they were cured and discharged from hospital and observed that even in the discharged COVID-19 patients, problems such as gastrointestinal and psychological disorder, compromised immunity, gut dysbiosis are prevalent. Altered peripheral lymphocyte subset, restored gut microbiota and alleviated gastrointestinal disorders were observe after FMT.
Early reports showed that 2–14.7% of SARS-CoV-2 infected patients had symptoms of diarrhea and 1–5% of the case had nausea and vomiting. Recently, Cheung et al. published a meta-analysis to report that up to 20% had gastrointestinal symptoms [3, 4, 16‐18]. Fecal samples from about 50% of COVID-19 patients were detected as SARS-CoV-2 positive, suggesting that the digestive tract might be another site for virus replication and activity [19, 20]. However, report about the after-effect of COVID-19 patients is rare. We are among the first to focus on the rehabilitation patient and report that even in the discharged COVID-19 patients, problems such as gastrointestinal disorder are not uncommon. However, these problems are largely underestimated and neglected. The latest COVID-19 report from China observed that up to 3 % of discharged patients were tested positive on a retest for SARS-CoV-2 and 35% of them had at least one symptom associated with active COVID-19 [21]. Thus, with the rapidly rising number of recovered patients, more and more attention will be paid to the health conditions of patient after the disease.
It has long been reported that respiratory viral infections can lead to alterations in gut microbiome, and gut microbiome disturbance would predispose patients to secondary bacterial infections [22, 23]. For COVID-19, the angiotensin converting enzyme 2 (ACE2) was reported to be a key receptor which facilitate the coronavirus to enter the host. ACE2 is not only expressed in respiratory tract, but also highly expressed in the gastrointestinal tract [24, 25], which may partly explained the gastrointestinal symptoms presented in COVID-19 patients. To date, the only direct evidence links COVID-19 to gut microbiota was reported by Siew et al., who investigated changes of fecal microbiomes of COVID-19 patients during hospitalization. Persistent alterations of fecal microbiome were observed in hospitalized patients. Fecal microbiota alterations were positively associated with fecal virus load of SARS-CoV-2 and the disease severity of COVID-19 [9]. In the current study, instead of focusing on hospitalized patients, we followed up COVID-19 patients and observed persistent changes in the fecal microbiome composition after they were cured and discharged from hospital. At the phylum level, the relative abundance of Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria were 41.0%, 42.9%, 9.2%, 4.0% respectively, which were different from that of the general population. In health population, the dominant phyla are Firmicutes and Bacteroidetes with a relative abundance of about 60% and 20% respectively [26‐28]. As for Actinobacteria and Proteobacteria, data from Asia population reported that the relative abundance was within the range of 0.12–0.22% and 0.01–0.03% respectively [29].
As Siew et al. reported in their study that targeting the intestinal microbiota might reduce disease severity of COVID-19 [9]. Actually, at the beginning of February 2020, the guidance of China’s National Health Commission (5th edition) recommended that probiotics can be used to maintain the intestinal microecological balance and prevent secondary bacterial infection when treating patients with severe COVID-19 infection. We further investigate whether FMT could be an effective strategy to improving the residual effect of COVID-19 by modifying the gut microbiome. We observed gut microbiome alteration and symptom alleviation after FMT, especially in patients with severe gastrointestinal symptoms. At the phylum level, the relative abundance of Actinobacteria (15%) and Proteobacteria (2.8%) were restored to the average level of the general population reported [29]. At the genera level, Bifidobacterium and Faecalibacterium significantly increased after FMT, especially in those COVID-19 patients with diarrhea or constipation. Bifidobacterium and Faecalibacterium are both dominant genera in human gut microbiota and are closely related to gut health [30‐32].
Gut microbiota could not only maintain immune homeostasis and immune responses at local mucosal surfaces, but also has distal protective effects and protect against respiratory influenza virus. Several studies have reported the application of FMT to improve immune functionality, thus exert indirect protective effect on virus influenza infection. Bradley et al. reported that antibiotic treatment can reduce intestinal microbiota, thus change the interferon signature driven by commensal in lung epithelia and promote early influenza virus replication in the respiratory tract. The effects can be reversed by fecal transplantation [15]. Tiffany et al. conducted FMT experiments on rhesus monkeys infected with chronic SIV during antiretroviral therapy. After antibiotic treatment, greatest microbiota shift was observed, while the frequencies of Th17 and Th22 in peripheral blood increased and the activation of CD4 T cells in intestinal tract decreased after FMT [33]. The latest evidence from Yongxi Zhang et al. reported persistent alterations of peripheral lymphocyte subset in COVID-19 patients, which confirmed the immunity dysfunction after SARS-CoV-2 infection [34]. In the current study, we also observed that the general distribution of 69 different types of lymphocytes differed between Pre-FMT and Post-FMT especially for B lymphocyte subset, which suggest targeting gut microbiota by FMT have favorable effects on the immunity system after SARS-CoV-2 infection.
Limitations of this study
One major limitation of this exploratory study is the limited sample size. Although the association between SARS-CoV-2 infection and gastrointestinal symptoms, gut dysbiosis in discharged patients requires validation from large scale studies, this pilot study for the time examined the after effect of SARS-CoV2 infection which include gastrointestinal symptoms, peripheral lymphocyte alteration and gut dysbiosis. Another major limitation is that the study is not randomized designed. Although establishing a causative relationship between FMT and gut microbiota regulation in discharged patients requires a parallel control group, it is the first time to examine the effect of FMT on the residual symptoms of SARS-CoV2 infection, and refer to FMT as a potential therapeutic and rehabilitative intervention for the COVID-19. We also attempted to evaluate the immune status and justify the beneficial effects of FMT from the perspective of immunity improvement. Further large scale studies with a randomized design to delineate the role of FMT and microbiome changes in SARS-CoV-2 infection and post-infection recovery.
Conclusions
Gastrointestinal and psychological symptoms, gut dysbiosis were observed in COVID-19 patients during post-infection recovery. After FMT, altered peripheral lymphocyte subset, restored gut microbiota and alleviated gastrointestinal disorders were observe, suggesting that FMT may serve as a potential therapeutic and rehabilitative intervention for the COVID-19.
Acknowledgements
This project was supported by National Natural Science foundation of China (81970156, 81970118). We thank Yuanfei Liu, Fusheng Liu and Bo Cao for assistance in recruiting patients, and thank Bohong Deng, Jinming Ke and Mingqiang Chu for assistance in preparing the manuscript.
Ethics approval and consent to participate
This study conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the local ethics committee (Approval number: 2020001). All patients provided written informed consent.
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.
